aibio
Listings ·
Lantern Pharma gets Nasdaq notice over $35,000,000 market value rule
Lantern has until March 24, 2027 to restore the $35,000,000 market value minimum after a Nasdaq notice dated September 25, 2026. Its 2025 net loss was $17.1 million.
LTRN Lantern Pharma Inc.
Lantern Pharma (LTRN) news LTRN offering and Nasdaq notice news
Latest Lantern Pharma news
- Financings
Lantern Pharma closes registered direct offering with about $4.0 million in gross proceeds
Lantern sold 1,469,725 shares at $1.09 each plus pre-funded warrants for up to 2,200,000 shares. A concurrent private placement of warrants for up to 3,669,725 shares needs stockholder approval before exercise.
- Financings
Lantern Pharma sets up $15,530,000 at-the-market stock program with ThinkEquity
ThinkEquity LLC will earn a 3.0% commission on shares sold. Lantern's public float was $46,607,112 as of July 3, 2025, which limits sales to one-third of that float in any 12-month period while the float stays below $75 million.
Lantern Pharma annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $11.5 million | $16.1 million |
| Net income (loss) | -$17.1 million | -$20.8 million |
| Cash from operations | -$15.7 million | -$17.8 million |
| Cash and equivalents | $4.4 million | $7.5 million |
| Short-term investments | $5.7 million | $16.5 million |
Questions about Lantern Pharma
Has Lantern Pharma raised money recently?
Our latest story on this, dated Sep 30, 2026: "Lantern Pharma closes registered direct offering with about $4.0 million in gross proceeds". The story links the filing or release it is based on. Read the story.
Has Lantern Pharma received a Nasdaq deficiency notice?
Our latest story on this, dated Oct 1, 2026: "Lantern Pharma gets Nasdaq notice over $35,000,000 market value rule". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Lantern Pharma?
Lantern Pharma Inc. trades under the ticker LTRN on NASDAQ.
Where is Lantern Pharma listed?
Lantern Pharma Inc. is listed on NASDAQ.
What is the SEC CIK of Lantern Pharma?
The SEC Central Index Key (CIK) for Lantern Pharma Inc. is 1763950. Its filings are on SEC EDGAR.
How many shares does Lantern Pharma have outstanding?
12,784,146 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-14.
Which country or territory is Lantern Pharma listed under?
Our directory records Lantern Pharma Inc. under United States.
What does Lantern Pharma do?
Our directory classifies Lantern Pharma Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Lantern Pharma?
The ISIN recorded for Lantern Pharma Inc. is US51654W1018.
Does aibio.space cover Lantern Pharma?
aibio.space lists Lantern Pharma Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Lantern Pharma incorporated?
SEC records list its state or country of incorporation as TX.
Is Lantern Pharma profitable?
Lantern Pharma Inc. reported a net loss of $17.1 million for the fiscal year ended Dec 31, 2025, and used $15.7 million of cash in operations, per its annual report to the SEC.
How much does Lantern Pharma spend on research and development?
$11.5 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Lantern Pharma have?
$7.4 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest Lantern Pharma (LTRN) stock news?
Our latest story on Lantern Pharma, dated Oct 1, 2026: "Lantern Pharma gets Nasdaq notice over $35,000,000 market value rule". Lantern has until March 24, 2027 to restore the $35,000,000 market value minimum after a Nasdaq notice dated September 25, 2026. Its 2025 net loss was $17.1 million. Source.
Investor discussion: Lantern Pharma
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
- Financings
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
- Financings
Reported a financing. SEC Form 424B5. Source
Stock chart
SEC filings and registration
- SEC name
- Lantern Pharma Inc.
- CIK
- 1763950
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- LTRN (Nasdaq)
- State or country of incorporation
- TX
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 1920 MCKINNEY AVENUE, DALLAS, TX, 75201
- Phone
- 972-277-1136
- Shares outstanding
- 12,784,146 as of 2026-08-10 (10-Q filed 2026-08-14)
- Former names
- Lantern Pharma
Recent filings
Listing details
- Company
- Lantern Pharma Inc.
- Ticker
- LTRN
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US51654W1018
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction